Revenue
2022
Calidi Biotherapeutics, Inc. (CLDI)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | — | — | — | $45,000 |
| Research & development | $9.7M | $8.9M | $13.0M | $7.3M |
| Operating expenses | $20.2M | $21.8M | $29.0M | $23.2M |
| Operating income | −$20.2M | −$21.8M | −$29.0M | −$23.1M |
| EBITDAderived | −$18.6M | −$20.2M | — | — |
| Net income | −$19.9M | −$22.1M | −$29.2M | −$25.4M |
| Basic EPSper diluted share | -$5.95 | -$35.70 | -$17.33 | $2.99 |
| Diluted EPSper diluted share | -$5.95 | -$35.70 | -$17.33 | $2.99 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 12, 2025Form 4 | Camaisa AllanDirector | SellCommon Stock · indirect | 850 | $1.46 | $1.2K | 77.0K |
| Aug 21, 2025Form 4 | Schoeneck James ADirector | BuyCommon Stock | 75.0K | $2.00 | $150.0K | 76.1K |
| Aug 21, 2025Form 4 | Schoeneck James ADirector | BuyWarrant (right to buy) · derivative | 75.0K | — | — | 75.0K |
| Aug 21, 2025Form 4 | Poma Eric EChief Executive Officer | BuyCommon Stock | 25.0K | $2.00 | $50.0K | 25.0K |
| Aug 21, 2025Form 4 | Poma Eric EChief Executive Officer | BuyWarrant (right to buy) · derivative | 25.0K | — | — | 25.0K |